166 related articles for article (PubMed ID: 36265694)
1. Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.
Huang R; Zheng J; Shao Y; Zhu L; Yang T
Prog Biophys Mol Biol; 2023 Jan; 177():34-41. PubMed ID: 36265694
[TBL] [Abstract][Full Text] [Related]
2. Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer.
Rashid S; Song D; Yuan J; Mullin BH; Xu J
J Cell Physiol; 2022 Mar; 237(3):1711-1719. PubMed ID: 34893976
[TBL] [Abstract][Full Text] [Related]
3. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
4. Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases.
Angata T
J Biomed Sci; 2020 Jan; 27(1):10. PubMed ID: 31900164
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
6. The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.
Andes FT; Adam S; Hahn M; Aust O; Frey S; Grueneboom A; Nitschke L; Schett G; Steffen U
Bone; 2021 Feb; 143():115665. PubMed ID: 33007530
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
8. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
9. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
10. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
11. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
13. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
14. Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway.
Li H; Zhu R; Liu X; Zhao K; Hong D
Oxid Med Cell Longev; 2022; 2022():3341038. PubMed ID: 36105484
[TBL] [Abstract][Full Text] [Related]
15. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy.
Wu Q; Wei X; Chen F; Huang M; Zhang S; Zhu L; Zhou L; Yang C; Song Y
Angew Chem Int Ed Engl; 2023 Dec; 62(52):e202312609. PubMed ID: 37955317
[TBL] [Abstract][Full Text] [Related]
17. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
[TBL] [Abstract][Full Text] [Related]
18. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
[TBL] [Abstract][Full Text] [Related]
19. The diverse functions of Siglec-15 in bone remodeling and antitumor responses.
Kang FB; Chen W; Wang L; Zhang YZ
Pharmacol Res; 2020 May; 155():104728. PubMed ID: 32112821
[TBL] [Abstract][Full Text] [Related]
20. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.
Beatson R; Tajadura-Ortega V; Achkova D; Picco G; Tsourouktsoglou TD; Klausing S; Hillier M; Maher J; Noll T; Crocker PR; Taylor-Papadimitriou J; Burchell JM
Nat Immunol; 2016 Nov; 17(11):1273-1281. PubMed ID: 27595232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
